Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3528963 | 0.81 | ALDH1A1 (0.53) | KDM4EHSD17B10SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL3531011 | 0.81 | ALDH1A1 (0.43) | KDM4EHSD17B10SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL3529749 | 0.80 | SLC25A1 (0.39) | KDM4EHSD17B10SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL3530734 | 0.80 | PPARG (0.45) | KDM4EHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL3526692 | 0.79 | MAPT (0.41) | ACLYTRPM8KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL3527410 | 0.78 | MCL1 (0.46) | ACLYFABP4ALDH1A1MEN1KMT2A | |
| SCHEMBL3531257 | 0.78 | PTGES2 (0.47) | ALDH1A1KMT2AHTT | |
| SCHEMBL3531726 | 0.76 | ALDH1A1 (0.45) | KDM4EHSD17B10SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL3529789 | 0.75 | POLB (0.49) | METAP2MEN1KMT2A | |
| SCHEMBL3528111 | 0.74 | GLO1 (0.46) | KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728002-B2 | Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors | LABORATOIRES FOURNIER S.A. (FR) | 2010-06-01 | — | — | US | disclosed |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | LABORATOIRES FOURNIER S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| US-7557122-B2 | Pyrrolopyridine compounds, method of making them and uses thereof | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | PPARD, PPARA, PPARG | ACLY 731/4885METAP2 2331/4885TRPM8 544/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | ACLY 404/4885METAP2 2400/4885TRPM8 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.